NCT03233711 2026-03-18
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
12 trialsNCT04929028 2026-03-18
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT07464236 2026-03-18
PEACHES 2
Albert Einstein College of Medicine
Phase NA Not yet recruiting
NCT06493019 2026-03-12
Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT04094454 2026-03-10
DILANA
University Hospital Heidelberg
Phase NA Recruiting
NCT06050707 2026-03-06
MAESTRO
University Health Network, Toronto
Phase 2 Recruiting
NCT04166318 2026-03-02
Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT05639972 2026-02-27
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
Rutgers, The State University of New Jersey
Phase 1/2 Recruiting
NCT06526819 2026-02-27
SMP-3124LP in Adults With Advanced Solid Tumors
Sumitomo Pharma America, Inc.
Phase 1/2 Recruiting
NCT04907643 2026-02-20
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Cedars-Sinai Medical Center
Phase NA Recruiting
NCT07425054 2026-02-20
HPV ctDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Advanced-Stage Anal Cancer
Case Comprehensive Cancer Center
Phase 2 Not yet recruiting
NCT04432597 2026-02-17
HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Active not recruiting